Background: Recent reports of thrombotic events after SARS-Cov-2 vaccination raised concern. However, mod- ifications of the most common coagulation parameters after vaccination are unknown. Aims: We measured parameters of coagulation including (i) basic coagulation tests, (ii) procedures aimed to assess the ex-vivo potential capacity to generate thrombin and (iii) in vivo thrombin activity. We also assessed anti-platelet factor 4 (aPF4) with two methods. Design: Laboratory measurements were performed for a cohort of subjects (n = 30) before (baseline) and after (7 and 21days after first dose, and 14days after second dose) SARS-Cov-2 vaccination. Results: All subjects received the Pfizer-BioNTech vaccine, and none developed symptomatic thrombotic events during the study period. None of the parameters showed clinically relevant variations at different time-points before and after vaccination. Only platelet count showed a slight increase, and F1.2 and the thrombin genera- tion parameters ETP and ETP-TM ratio, showed a small decline, at the last time-point after vaccination when compared to baseline. aPF4 was negative in all the subjects, except two, who were positive (one with the chemiluminescent and the other with the ELISA assay). Conclusions: The study shows no modifications of the coagulation parameters nor the presence of biochemical signs of coagulation activation following the administration of the Pfizer-BioNTech vaccine.

No changes of parameters nor coagulation activation in healthy subjects vaccinated for {SARS}-Cov-2 / F. Payvandi, E. Scalambrino, M. Clerici, A. Lecchi, N. Revelli, R. Palla, R. Gualtierotti, D. Prati, A. Tripodi. - In: THROMBOSIS UPDATE. - ISSN 2288-8926. - 4(2021 Aug), pp. 100059.1-100059.3. [10.1016/j.tru.2021.100059]

No changes of parameters nor coagulation activation in healthy subjects vaccinated for {SARS}-Cov-2

F. Payvandi
Primo
;
E. Scalambrino
Secondo
;
M. Clerici;R. Palla;R. Gualtierotti;
2021-08

Abstract

Background: Recent reports of thrombotic events after SARS-Cov-2 vaccination raised concern. However, mod- ifications of the most common coagulation parameters after vaccination are unknown. Aims: We measured parameters of coagulation including (i) basic coagulation tests, (ii) procedures aimed to assess the ex-vivo potential capacity to generate thrombin and (iii) in vivo thrombin activity. We also assessed anti-platelet factor 4 (aPF4) with two methods. Design: Laboratory measurements were performed for a cohort of subjects (n = 30) before (baseline) and after (7 and 21days after first dose, and 14days after second dose) SARS-Cov-2 vaccination. Results: All subjects received the Pfizer-BioNTech vaccine, and none developed symptomatic thrombotic events during the study period. None of the parameters showed clinically relevant variations at different time-points before and after vaccination. Only platelet count showed a slight increase, and F1.2 and the thrombin genera- tion parameters ETP and ETP-TM ratio, showed a small decline, at the last time-point after vaccination when compared to baseline. aPF4 was negative in all the subjects, except two, who were positive (one with the chemiluminescent and the other with the ELISA assay). Conclusions: The study shows no modifications of the coagulation parameters nor the presence of biochemical signs of coagulation activation following the administration of the Pfizer-BioNTech vaccine.
coagulation; COVID-19; SARS-Cov-2; vaccine; mRNA vaccine;
Settore MED/09 - Medicina Interna
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2666572721000286-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 359.18 kB
Formato Adobe PDF
359.18 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/905929
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact